Corvus Pharmaceuticals (CRVS) Financials: Revenue & Earnings

CRVS price $10.44 -0.10 -0.95%

Ticker
CRVS
Price
$10.44
Change
-0.10 -0.95%
Market cap ?
$878.22M
Beta ?
0.86
Sector
Healthcare
Industry
Biotechnology

Fair value

CRVS fair value $5.18. Price $10.44. Price is 102% above fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Model uncertainty high for this stock

Compare CRVS

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-03—-0.19——
2026-08-06-0.19-0.16——
2026-05-07-0.15-0.14——
2026-03-12-0.15-0.14—775.00K
2025-11-04-0.12-0.14——
2025-08-07-0.10-0.13——
2025-05-08-0.13-0.13——
2025-03-25-0.18-0.12——
2024-11-12-0.60-0.11——
2024-08-06-0.07-0.12——
2024-05-06-0.12-0.12——
2024-03-19-0.14-0.14246.00K—
2023-11-07-0.12-0.16——
2023-08-08-0.14-0.14——
2023-05-08-0.17-0.16——
2023-03-28-0.210.23——
2022-11-03-0.32-0.16——
2022-08-08-0.18-0.19——
2022-05-05-0.18-0.14——
2022-03-10-0.20-0.20——
2021-11-01-0.24-0.30——
2021-08-02-0.28-0.32——
2021-04-29-0.34-0.33——
2021-03-25-0.35-0.32——
2020-10-29-0.33-0.25——
2020-07-30-0.36-0.30——
2020-04-30-0.44-0.40——
2020-03-05-0.38-0.33——
2019-10-29-0.37-0.40——
2019-08-01-0.44-0.42——
2019-05-09-0.40-0.40——
2019-03-07-0.36-0.40——
2018-11-01-0.36-0.46——
2018-08-02-0.40-0.63——
2018-05-03-0.63-0.71——
2018-03-01-0.58-0.66——
2017-11-02-0.62-0.85——
2017-08-03-0.73-0.74——
2017-05-04-0.79-0.77——
2017-03-10-0.55-0.57——

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-06-11Moore David ScottBuy21.70K$11.53250.24K
2026-06-11Moore David ScottBuy15.00K$11.60174.00K
2026-06-11CLARK IAN TBuy15.00K$11.60174.00K
2026-06-11Grais LindaBuy15.00K$11.60174.00K
2026-06-11Thompson Peter A.Buy15.00K$11.60174.00K
2026-06-11van den Broek RichardBuy15.00K$11.60174.00K
2026-05-18MILLER RICHARD A MDBuy1.93K$12.0123.20K
2026-05-18MILLER RICHARD A MDBuy5.00K$12.0560.25K
2026-04-23Chan Andrew C.Buy30.00K$16.02480.60K
2026-04-23Chan Andrew C.Other0——
2026-01-28Thompson Peter A.Buy15.00K$2.1231.80K
2026-01-28Thompson Peter A.Buy15.00K$1.6424.60K
2026-01-28Thompson Peter A.Buy15.00K$2.4937.35K
2026-01-28Thompson Peter A.Buy15.00K$0.9614.47K
2026-01-28Thompson Peter A.Buy15.00K$0.9914.85K
2026-01-28Thompson Peter A.Buy15.00K$2.6039.00K
2026-01-28Thompson Peter A.Buy15.00K$2.7441.10K
2026-01-28Thompson Peter A.Buy15.00K$3.2749.05K
2026-01-28Thompson Peter A.Buy15.00K$2.0030.00K
2026-01-28Thompson Peter A.Buy15.00K$3.6154.15K
2026-01-28Thompson Peter A.Buy15.00K$12.50187.50K
2026-01-28Thompson Peter A.Buy15.00K$9.70145.50K
2026-01-28Thompson Peter A.Buy30.00K$15.00450.00K
2026-01-28Thompson Peter A.Sell15.00K$2.1231.80K
2026-01-28Thompson Peter A.Sell15.00K$1.6424.60K
2026-01-28Thompson Peter A.Sell30.00K$15.00450.00K
2026-01-28Thompson Peter A.Sell15.00K$9.70145.50K
2026-01-28Thompson Peter A.Sell15.00K$12.50187.50K
2026-01-28Thompson Peter A.Sell15.00K$3.6154.15K
2026-01-28Thompson Peter A.Sell15.00K$2.0030.00K
2026-01-28Thompson Peter A.Sell15.00K$2.7441.10K
2026-01-28Thompson Peter A.Sell15.00K$2.6039.00K
2026-01-28Thompson Peter A.Sell15.00K$0.9914.85K
2026-01-28Thompson Peter A.Sell15.00K$0.9614.47K
2026-01-28Thompson Peter A.Sell15.00K$2.4937.35K
2026-01-28Thompson Peter A.Sell15.00K$3.2749.05K
2025-12-04Jones William BentonBuy400.00K$8.813.52M
2025-12-04MILLER RICHARD A MDBuy1.00M$8.818.81M
2025-12-04Arcara JeffreyBuy100.00K$8.81881.00K
2025-12-04LEA LEIVBuy400.00K$8.813.52M
2025-10-02Moore David ScottBuy30.00K$7.04211.20K
2025-10-02Moore David ScottOther0——
2025-06-27ORBIMED ADVISORS LLCBuy1.40M$3.504.89M
2025-06-27ORBIMED ADVISORS LLCSell1.18M$4.164.89M
2025-06-27ORBIMED ADVISORS LLCSell1.40M$3.504.89M
2025-06-27Thompson Peter A.Buy1.40M$3.504.89M
2025-06-27Thompson Peter A.Sell1.18M$4.164.89M
2025-06-27Thompson Peter A.Sell1.40M$3.504.89M
2025-06-12Grais LindaBuy15.00K$4.2463.60K
2025-06-12CLARK IAN TBuy15.00K$4.2463.60K
2025-06-12Morrison Scott WBuy15.00K$4.2463.60K
2025-06-12Thompson Peter A.Buy15.00K$4.2463.60K
2025-06-04Jones William BentonBuy19.36K$3.5067.75K
2025-06-04Jones William BentonSell19.36K$3.5067.75K
2025-05-07MILLER RICHARD A MDBuy559.07K$3.501.96M
2025-05-07MILLER RICHARD A MDSell559.07K$3.501.96M
2025-04-08van den Broek RichardBuy30.00K$2.8284.60K
2025-04-08van den Broek RichardOther0——
2024-12-20Arcara JeffreyBuy50.00K$4.99249.50K
2024-12-20Jones William BentonBuy300.00K$4.991.50M
2024-12-20LEA LEIVBuy300.00K$4.991.50M
2024-12-20MILLER RICHARD A MDBuy750.00K$4.993.74M
2024-06-13Grais LindaBuy15.00K$2.1231.80K
2024-06-13CLARK IAN TBuy15.00K$2.1231.80K
2024-06-13Morrison Scott WBuy15.00K$2.1231.80K
2024-06-13Gould Terry PBuy15.00K$2.1231.80K
2024-06-13Thompson Peter A.Buy15.00K$2.1231.80K
2024-05-10MILLER RICHARD A MDSell302.02K——
2024-05-06Thompson Peter A.Buy1.44M$0.00144
2024-05-06Thompson Peter A.Buy1.40M$3.504.89M
2024-05-06ORBIMED ADVISORS LLCBuy1.44M$0.00144
2024-05-06ORBIMED ADVISORS LLCBuy1.40M$3.504.89M
2024-05-06Jones William BentonBuy20.00K$1.7334.62K
2024-05-06Jones William BentonBuy19.36K$3.5067.75K
2024-05-06MILLER RICHARD A MDBuy577.63K$1.731000.00K
2024-05-06MILLER RICHARD A MDBuy559.07K$3.501.96M
2024-02-28Arcara JeffreyBuy400.00K$2.30920.00K
2024-02-02Arcara JeffreyOther0——
2023-12-06MILLER RICHARD A MDBuy500.00K$1.64820.00K
2023-12-06LEA LEIVBuy200.00K$1.64328.00K
2023-12-06Jones William BentonBuy200.00K$1.64328.00K
2023-12-06Mitchell Edith P.Buy15.00K$1.6424.60K
2023-12-06Grais LindaBuy15.00K$1.6424.60K
2023-12-06CLARK IAN TBuy15.00K$1.6424.60K
2023-12-06Morrison Scott WBuy15.00K$1.6424.60K
2023-12-06Gould Terry PBuy15.00K$1.6424.60K
2023-12-06Thompson Peter A.Buy15.00K$1.6424.60K
2023-06-15Thompson Peter A.Buy15.00K$2.4937.35K
2023-06-15Gould Terry PBuy15.00K$2.4937.35K
2023-06-15CLARK IAN TBuy15.00K$2.4937.35K
2023-06-15Morrison Scott WBuy15.00K$2.4937.35K
2023-06-15Grais LindaBuy15.00K$2.4937.35K
2023-06-15Mitchell Edith P.Buy15.00K$2.4937.35K
2023-05-15Grais LindaBuy10.00K$2.4524.50K
2023-03-31MILLER RICHARD A MDBuy800.00K$0.91728.00K
2022-12-20Jones William BentonBuy20.00K$0.7915.80K
2022-12-14LEA LEIVBuy4.00K$0.843.36K
2022-12-14MILLER RICHARD A MDBuy10.00K$0.787.81K
2022-12-13LEA LEIVBuy30.00K$0.7422.27K
2022-12-13MILLER RICHARD A MDBuy50.00K$0.7437.02K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 188, holders +15 vs prior quarter. Ownership 76.79%.

HolderSharesChangeChange %Value
ORBIMED ADVISORS LLC7.17M00.00%107.05M
BLACKROCK, INC.7.14M978.39K+15.88%106.65M
STATE STREET CORP4.47M908.10K+25.47%66.84M
PRICE T ROWE ASSOCIATES INC /MD/3.79M871.83K+29.88%56.61M
VANGUARD CAPITAL MANAGEMENT LLC3.29M58.17K+1.80%49.19M
ADAMS STREET PARTNERS LLC3.28M00.00%48.94M
VIVO CAPITAL, LLC2.81M00.00%41.92M
WELLINGTON MANAGEMENT GROUP LLP2.73M413.12K+17.82%40.81M
PERCEPTIVE ADVISORS LLC2.67M375.00K+16.36%39.85M
DEEP TRACK CAPITAL, LP2.49M400+0.02%37.23M
BRAIDWELL LP2.13M373.50K+21.31%31.77M
GEODE CAPITAL MANAGEMENT, LLC1.85M140.92K+8.23%27.70M
FORESITE CAPITAL MANAGEMENT VI LLC1.83M00.00%27.36M
GOLDMAN SACHS GROUP INC1.58M35.54K+2.31%23.55M
HOOD RIVER CAPITAL MANAGEMENT LLC1.57M236.70K+17.73%23.48M
MORGAN STANLEY1.34M-1.15M-46.19%20.09M
BOXER CAPITAL MANAGEMENT, LLC1.10M00.00%16.43M
CATALIO CAPITAL MANAGEMENT, LP1.08M188.96K+21.18%16.15M
MILLENNIUM MANAGEMENT LLC1.05M181.62K+20.96%15.66M
VANGUARD PORTFOLIO MANAGEMENT LLC814.75K144.85K+21.62%12.17M
TWO SIGMA INVESTMENTS, LP785.21K245.34K+45.44%11.73M
BANK OF AMERICA CORP /DE/757.80K520.79K+219.74%11.32M
ADAGE CAPITAL PARTNERS GP, L.L.C.750.00K00.00%11.21M
EVERSEPT PARTNERS, LP747.99K747.99KNew11.18M
EMERALD ADVISERS, LLC685.68K-533-0.08%10.24M

Earnings and financials

Corvus Pharmaceuticals, Inc. (CRVS) trades at $10.44, with a market cap of $878.22M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Corvus Pharmaceuticals (CRVS) Financials: Revenue & Earnings

CRVS$10.44-0.10 -0.95%

$878.22M

Market Cap

—

P/E

—

Forward P/E

—

Score

Price History